Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug684 | Capillary Collection & Testing Wiki | 0.58 |
| drug1349 | Global Longitudinal Strain Wiki | 0.58 |
| drug3536 | Venous Draw & Testing Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug616 | COVID-19 experience surveys Wiki | 0.58 |
| drug685 | Capillary and salivary sampling Wiki | 0.58 |
| drug681 | Cannabidiol Wiki | 0.41 |
| drug3268 | Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Wiki | 0.41 |
| drug617 | COVID-19 exposure Wiki | 0.41 |
| drug2340 | PLACEBO Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001638 | Cardiomyopathy HPO | 1.00 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.10 |
Navigate: Correlations HPO
There are 3 clinical trials
COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.
Description: T-cell immunophenotype
Measure: T-cell immunophenotype Time: 12 months from enrollmentDescription: death, survival to discharge
Measure: Mortality Time: 12 months from enrolmentDescription: Admission to the intensive care
Measure: ITU admission Time: 12 months from enrolmentDescription: Defined by troponin rise to >99th centile
Measure: Myocardial injury Time: 12 months from enrolmentThe effects of severe acute respiratory syndrome SARS-Cov-2 (Covid-19) on the myocardium and their role in the clinical course of infected patients are still unknown. Epidemiological studies report biological myocardial involvement in 10 to 25% of cases. The objective of this study is to cardiac phenotype using comprehensive cardiac imaging tools of patients infected with Covid 19 in order to explore the functional impact of the infection on the myocardium.
Description: Left ventricular function evaluated by global longitudinal strain
Measure: Left ventricular function Time: Day 0Description: Left ventricular function evaluated by global longitudinal strain
Measure: Left ventricular function Time: Day 3Description: Left ventricular function evaluated by global longitudinal strain
Measure: Left ventricular function Time: Day 7Description: Cytokine rate
Measure: inflammatory biological parameters Time: Day 0All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment. The HeartHive COVID-19 study is an international online pilot observational cohort study evaluating the impact and clinical outcomes of the COVID-19 pandemic on subjects enrolled in the HeartHive. Cardiomyopathies are progressive diseases, and there is a need to better understand what factors affect the chances of developing cardiomyopathy, and how the condition progresses. The impact of the COVID-19 pandemic on patients with cardiomyopathy has not been explored and represents a critical unmet need. Insights into exposure, healthcare outcomes, behavioural changes and the psychosocial ramifications of the pandemic are required to better understand the health needs of this population during these unprecedented circumstances and to adapt clinical services to meet these. The study will entail completing serial online surveys during the pandemic. This study uses The Heart Hive - an international, online registry of patients with self-reported clinically diagnosed cardiomyopathy, and people without heart disease. Participants enrol and upload their own data through the website. It is the second research study that will be offered to registry participants and delivered through The Heart Hive platform.
Description: Collected from serial online surveys
Measure: Qualitative measures of exposure, perception of risk, behaviour, and experience during the COVID-19 pandemic. Time: 2 yearsDescription: Hospital admissions and deaths due to COVID-19, incidents of major adverse cardiovascular events
Measure: Health Outcomes Time: 2 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports